Kiora Pharmaceuticals
Most recent annual filing: 2026-01-15
Pipeline (5 active programs)
KIO-104
Small Molecule Target: DHODH
- Diabetic Macular Edema
- Posterior Non-Infectious Uveitis
- Undisclosed indication
KIO-101
Small Molecule Target: DHODH
Technology platforms
Ion Channel Modulator
Novel ion channel modulator platform with membrane-calming effects; primary focus on retinal disease (reducing pathological retinal hyperactivity); exploratory expansion into neurological disorders including epilepsy where neuronal hyperexcitability is implicated
Biotech Distilled coverage (3)
- 2026-04-27 UPDATE: KIORA PHARMACEUTICALS INC (KPRX) - Perceptive Shows Up, Nature Medicine Prints, and the Warrant Structure Tells You the Plan 🔒 Paid
- 2026-03-28 UPDATE: Kiora Pharmaceuticals (KPRX) - A 12-Month Delay, a $4.6M Impairment, and the Value of Deep-Pocketed Partners 🔒 Paid
- 2026-03-09 Kiora Pharmaceuticals (KPRX): Scientific Deep Dive for KIO-301 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.